Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893626 | 0.82 | ABHD6 (0.40) | TMEM97SIGMAR1KMT2APTGDR2 | |
| SCHEMBL29554819 | 0.80 | TMEM97 (0.58) | TMEM97SIGMAR1MEN1ALDH1A1GAA | |
| SCHEMBL4795463 | 0.80 | TMEM97 (0.58) | TMEM97SIGMAR1MEN1ALDH1A1GAA | |
| SCHEMBL28097001 | 0.80 | PTGDR2 (0.60) | TMEM97SIGMAR1PTGDR2 | |
| SCHEMBL30276669 | 0.80 | TMEM97 (0.58) | TMEM97SIGMAR1MEN1ALDH1A1GAA | |
| SCHEMBL28096940 | 0.80 | TMEM97 (0.58) | TMEM97SIGMAR1MEN1ALDH1A1GAA | |
| SCHEMBL324228 | 0.78 | TMEM97 (0.67) | TMEM97SIGMAR1MEN1KMT2ANPC1 | |
| SCHEMBL24495279 | 0.77 | TMEM97 (0.58) | TMEM97SIGMAR1MEN1ALDH1A1GAA | |
| SCHEMBL16269012 | 0.75 | TMEM97 (0.53) | TMEM97SIGMAR1MEN1ALDH1A1GAA | |
| SCHEMBL28097002 | 0.74 | PTGDR2 (0.60) | TMEM97SIGMAR1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | TMEM97 265/4885SIGMAR1 256/4885MEN1 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.